Recent studies suggest even low dosages of oestrogen currently used for treatment of prostate cancer increase cardiovascular morbidity. In addition, relapse following growth of hormone-insensitive cells, and the present observations of further evidence of immunosuppression demonstrated by the significant (p < 0.001) effect of DES on the lytic activity of natural killer cells vs. the negligible effect of the luteinizing - hormone - releasing - hormone, leuprolide (Lupron) raises concern that the palliative effects of oestrogen therapy are possibly further compromised by a reduction in immunosurveillance to tumour, or equally important, by a decreased capacity to cope with infectious agents.
|Original language||English (US)|
|Number of pages||4|
|State||Published - 1988|
ASJC Scopus subject areas
- Cancer Research